Adaptimmune Therapeutics plc (ADAP)

Oncology Corporate Profile

HQ Location

91 Park Drive, Milton Park
Abingdon
Oxfordshire, OX14 4RY

Company Description

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the body's own machinery ' the T-cell ' to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune's lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen.

Website: http://www.adaptimmune.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
NY-ESO TCRT-cell receptorMelanomaIGlaxoSmithKline
NY-ESO TCRT-cell receptorMultiple MyelomaIGlaxoSmithKline
NY-ESO TCRT-cell receptorNon Small Cell Lung Cancer (NSCLC)IGlaxoSmithKline
MAGE-A10 TCRT-cell receptorNon Small Cell Lung Cancer (NSCLC)I
NY-ESO TCRT-cell receptorOvarian cancerIGlaxoSmithKline
MAGE-A10 TCRT-cell receptorBladder cancerPreclinical
MAGE-A10 TCRT-cell receptorHead & Neck cancerPreclinical
AFP TCRT-cell receptorHepatocellular carcinoma (HCC)Preclinical
MAGE-A10 TCRT-cell receptorMelanomaPreclinical

View additional information on product candidates here »

Source: http://www.adaptimmune.com/

Recent News Headlines

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/16/2017 06:17 am

5/16/2017 06:17 am

5/16/2017 06:17 am

5/16/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/3/2017 12:17 pm

5/2/2017 06:17 am

4/10/2017 12:17 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

4/9/2017 06:17 am

Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit

3/27/2017 08:03 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 27, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’ s Chief Executive Officer, ...

Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

3/27/2017 03:03 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, UK, March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune") (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing ...

Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

3/27/2017 03:02 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, UK, March 27, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering ...

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

3/22/2017 02:00 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced ...